Regenerex Pharma's SEC filings document the public-company reporting record of a Nevada wound-care issuer quoted under RGPX. Recent 8-K filings disclose governance and officer matters, including finance-function changes, board committee review, and reassignment of CFO duties, as well as a fiscal-year-end change and transition-period reporting.
The filing record also includes Form 12b-25 notices for delayed annual and quarterly reports, with narrative disclosures about completing financial statements and reconciling quarterly financial data. The filings identify the company as an emerging growth company, state that it has no securities registered under Section 12(b), and provide formal records on reporting obligations, governance oversight, financial-reporting controls, and capital-structure status.
REGENEREX PHARMA, INC. (RGPX) reports that its independent registered public accounting firm, dbbmckennon, resigned effective August 31, 2026, after serving in that role since 2017. The board acknowledged and accepted the firm’s internal decision to cease providing services.
dbbmckennon’s reports on the company’s financial statements for the fiscal years ended March 31, 2025 and December 31, 2025 contained no adverse or disclaimed opinions and were not qualified, but did include an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern, and for the April 1–December 31, 2025 transition period also noted a revision to disclose related party transactions. The company states there were no disagreements or reportable events with dbbmckennon under Regulation S‑K and is in the process of engaging a successor auditor while working to complete outstanding periodic reports and bring its SEC filings current.
REGENEREX PHARMA, INC. (RGPX) reports that its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 has been completed and filed, but after the applicable deadline. Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 remain unfiled and are delinquent, and the company did not submit Notifications of Late Filing on Form 12b-25 for these periods. Management describes substantial additional accounting, reconciliation, and review work undertaken to complete the 2025 Form 10-K and to prepare the outstanding quarterly financial statements, and states it is working with internal staff and external advisors to become current in SEC reporting as promptly as practicable. The company states it does not currently anticipate changes to its operations or business strategy due to the filing delays but cautions that financial information for the affected quarters is incomplete and should be evaluated together with other SEC filings.
Regenerex Pharma, Inc. (RGPX) is a Nevada-based wound-care company focused on proprietary technologies for chronic and acute wounds, centered on its QBx™ platform and primary product, Accelerex™. Regenerex targets diabetic ulcers, pressure ulcers, burns and surgical wounds and highlights clinical data it states show high closure rates in non‑healing chronic wounds.
For the nine months ended December 31, 2025, the company generated no revenue and reported a net loss of $2,543,211, similar to the $2,527,041 loss for the year ended March 31, 2025. Cash declined to $11,049 from $653,025, while current liabilities reached $5,169,186, resulting in a stockholders’ deficit of $5,001,304. The auditor and management disclose substantial doubt about Regenerex’s ability to continue as a going concern.
Operations have been funded by equity sales and related‑party and other notes payable; the company is seeking an additional $5,000,000 by September 2026. A March 2025 bank account hack led to a theft of funds, with partial recovery and a bank settlement recorded. Regenerex changed its fiscal year end to December 31 and discloses multiple related‑party arrangements, including an asset purchase with up to $10,000,000 contingent consideration and significant notes payable to related parties. The company reports new litigation it has initiated against its former CFO and a related entity, with outcomes not yet determined.
Regenerex Pharma, Inc. placed its Chief Financial Officer, Kenneth Perry, on paid administrative suspension leave effective March 31, 2026, after the Board cited concerns about compliance with Board directives, financial oversight, corporate governance, and the company’s financial reporting processes and internal controls. The company states that these matters are under review and that no final determinations have been made. Mr. Perry remains an employee and continues to receive his base salary and benefits. Effective April 1, 2026, the Board appointed Don E. Ray as Interim Chief Financial Officer on a 90-day initial term with an interim salary of $150,000 annually, bringing extensive public-company auditing and automotive industry financial leadership experience.
Regenerex Pharma, Inc. notified the SEC on Form 12b-25 that it cannot timely file its Form 10-K for the period ended December 31, 2025. The delay is due to an ongoing internal review initiated by independent board members and required coordination with external auditors and legal counsel. Auditors have advised they cannot complete audit procedures until sufficient progress in the review is made. The company states the review may lead to adjustments to previously reported financial information but cannot reasonably estimate any magnitude. The registrant intends to file the Form 10-K as soon as practicable after the review and audit work are completed.
Regenerex Pharma, Inc. reported no revenue for the six months ended September 30, 2025 and a larger net loss of $1,477,596, compared with $802,132 a year earlier. Higher research and development, payroll, lease and IT expenses drove the increased loss. Cash and equivalents fell sharply to $11,659 from $653,025, while total assets were $617,764 and total liabilities $5,316,564, resulting in a stockholders’ deficit of $4,698,800. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern and is seeking additional capital through equity and debt financing. During the period, Regenerex raised $500,000 by issuing 500,000 shares at $1.00 per share with matching warrants and adopted a 2025 equity plan with 20 million shares, including 4,000,000 options granted to the CFO. The company is developing advanced wound care products and expects to launch sales in the quarter ending December 31, 2025.
Regenerex Pharma, Inc. filed a Form 12b-25 to notify a late filing of its Form 10-Q for the quarter ended September 30, 2025. The company explains that it could not complete the quarterly report on time due to unanticipated delays in compiling and reconciling financial data, including additional time needed to obtain and verify information from third-party service providers.
Regenerex states that the Form 10-Q will be filed within the allowed extension period, which for a quarterly report is up to five calendar days after the original due date. The company confirms that all other required periodic reports over the past 12 months have been filed and indicates it does not anticipate any significant change in results of operations compared with the same quarter of the prior year.